Blow by Graham Steell
Specialty: Cardiovascular.
Why it occurs
- Severe pulmonary arterial hypertension (primary or idiopathic)
- Chronic hypertensive pulmonary thromboembolism (Group 4)
- Chronic obstructive pulmonary disease (COPD) with severe cor pulmonale
- Advanced chronic left ventricular failure with severe passive pulmonary hypertension (Group 2)
- Chronic narrow mitral stenosis (classic cause described by Graham Steell)
Initial workup
Transthoracic Doppler echocardiogram to quantify the pulmonary artery systolic pressure (PSAP) using the tricuspid regurgitation gradient and the diastolic pulmonary regurgitation velocity (pulmonary diastolic pressure), measure the systolic excursion of the plane of the tricuspid annulus (TAPSE <17 mm indicates a poor prognosis) and assess the degree of dilation and systolic dysfunction of the right ventricle; Right heart catheterization for standard invasive measurement of pulmonary pressures, cardiac output, and pulmonary vascular resistance (PVR); Computed tomography (CT angiography) of the chest to rule out chronic pulmonary thromboembolism.
red flags
High-pitched, decreasing, aspirational diastolic murmur, audible in the second or third left intercostal space (high left sternal border) that begins immediately after the pulmonary component of the second heart sound (accentuated and palpable R2P), associated with extreme dyspnea at rest or minimal effort, central cyanosis refractory to the administration of oxygen, oppressive retrosternal pain on effort (right ventricular ischemia), syncope of recurrent effort, generalized edema, ascites or congestive hepatomegaly. It indicates extreme pulmonary hypertension with functional pulmonary insufficiency and severe right ventricular dysfunction with high risk of cardiovascular collapse.
Standard management
- Treprostinil — prostacyclin analog indicated in severe pulmonary arterial hypertension to induce vasodilation of the pulmonary vasculature and reduce right ventricular afterload; Continuous subcutaneous or intravenous infusion adjusted according to pulmonary hypertension protocol
- Bosentan — dual endothelin receptor antagonist indicated to improve exercise tolerance and slow the progression of PAH; 62.5 to 125 mg twice daily orally, monitoring hepatic transaminases
- Sildenafil — phosphodiesterase-5 inhibitor indicated to promote nitric oxide-mediated vasodilation; 20 mg three times a day orally
- Furosemide (loop diuretic for the control of right ventricular volume overload and associated congestive hepatomegaly; 40 mg once daily orally, closely monitoring electrolyte balance).
Educational guidance for study. It is NOT a prescription recommendation. The actual choice depends on the cause, the patient, and current guidelines.
- Area
- Cardiovascular
- Listed causes
- 5
- Treatment options
- 4